Valuation: Genexine, Inc.

Market Cap 243B 157M 138M 127M 118M 222M 14.89B 227M 1.52B 590M 7.31B 588M 575M 25.44B P/E 2022
-8.34x
P/E 2023 -5.99x
Enterprise Value 246B 159M 139M 128M 119M 225M 15.07B 230M 1.54B 597M 7.4B 595M 582M 25.75B EV / Sales 2022
33x
EV / Sales 2023 93.4x
Free-Float
81.34%
Yield 2022 *
-
Yield 2023 -
04-28 Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models CI
03-16 Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101) CI
03-16 Egret Therapeutics Inc. signed a non-binding Memorandum of Understanding to acquire full right, title, and interest in lead asset EGT-101 (GX-P1) from Genexine, Inc.. CI
01/10/25 Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
23/09/25 Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
07/03/25 Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan MT
01/10/24 Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc. CI
04/07/24 Genexine, Inc. Appoints Jaehyun Choi as Head of R&D CI
26/06/24 Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. CI
14/05/24 Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
14/11/23 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23/10/23 Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority CI
31/08/23 Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday MT
1 day+0.59%
1 week-0.39%
Current month+0.59%
1 month-28.05%
3 months-46.64%
6 months-45.78%
Current year-45.78%
1 week 2,210
Extreme 2210
2,670
1 month 2,210
Extreme 2210
3,620
Current year 2,210
Extreme 2210
7,490
1 year 2,210
Extreme 2210
7,490
3 years 2,210
Extreme 2210
12,300
5 years 2,210
Extreme 2210
75,538.46
10 years 2,210
Extreme 2210
146,384.62
Manager TitleAgeSince
Chief Executive Officer 51 26/03/2025
Chief Executive Officer 61 27/01/2023
Corporate Officer/Principal 49 01/01/2022
Director TitleAgeSince
Chairman 68 -
Director/Board Member 74 29/03/2022
Director/Board Member 61 27/01/2023
Date Insider Type Main position Quantity % Market Cap.
22/10/24Others 563,723 1.3580%
22/10/24Others 156,632 0.3773%
22/10/24Others

Chief Executive Officer

1,691,165 4.0741%
Change 5-day change 1-year change 3-year change Capi.($)
+0.59%-0.39%-47.30%-75.10% 74.5M
-2.19%+6.01%+66.90%+123.30% 56.21B
+0.55%+8.49%+77.09%+100.93% 55.38B
+0.93%+4.11%-12.64%-12.98% 23.75B
+0.36%+3.42%+9.61%+407.11% 23.19B
+4.05%+8.88%+40.51%-5.41% 18.14B
+0.28%+5.51%+36.93%-30.23% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.86B
-0.83%+2.06%+23.70%+182.37% 13.56B
+7.75%+14.06%+43.04% - 12.97B
Average +1.32%+6.61%+41.27%+114.95% 23.6B
Weighted average by Cap. +0.56%+6.60%+54.91%+129.94%

Financials

2022 2023
Net sales 16.14B 10.41M 9.14M 8.41M 7.84M 14.78M 990M 15.08M 101M 39.2M 486M 39.08M 38.23M 1.69B 4.43B 2.85M 2.51M 2.31M 2.15M 4.05M 271M 4.14M 27.75M 10.75M 133M 10.72M 10.49M 464M
Net income -55.97B -36.1M -31.69M -29.17M -27.18M -51.27M -3.43B -52.31M -351M -136M -1.68B -136M -133M -5.86B -66.87B -43.13M -37.87M -34.85M -32.48M -61.25M -4.1B -62.5M -419M -162M -2.01B -162M -158M -7B
Net Debt 62.14B 40.08M 35.19M 32.39M 30.18M 56.92M 3.81B 58.07M 390M 151M 1.87B 150M 147M 6.51B 2.94B 1.9M 1.67M 1.53M 1.43M 2.7M 181M 2.75M 18.46M 7.15M 88.63M 7.13M 6.98M 308M
Logo Genexine, Inc.
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Employees
86
Date Price Change Volume
01/07/26 ₩2,540.00 +0.59% 115,503
30/06/26 ₩2,525.00 -4.72% 148,089
29/06/26 ₩2,650.00 +15.22% 224,586
26/06/26 ₩2,300.00 -6.12% 256,777
25/06/26 ₩2,450.00 -3.92% 194,017
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A095700 Stock